Business Context and Reporting Period
Company: Travere Therapeutics, Inc. (TVTX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 6, 2026
Event Date: May 11, 2026 (Closing Date)
Summary: The Company completed a registered underwritten public offering of senior convertible notes to raise capital for debt refinancing and general corporate purposes.
Key Financial Metrics
| Metric | Value |
|---|---|
| Total Principal Amount Offered | $525.0 million |
| Base Offering Amount | $475.0 million |
| Over-Allotment Exercised | $50.0 million |
| Estimated Net Proceeds | Approximately $508.5 million |
| Interest Rate (New Notes) | 0.50% per annum |
| Maturity Date | May 15, 2032 |
| Initial Conversion Price | Approximately $64.90 per share |
| Initial Conversion Rate | 15.4078 shares per $1,000 principal |
| Maximum Potential Dilution | 11,729,182 shares (subject to adjustments) |
Material Changes and Debt Refinancing
The filing details a significant capital structure change involving the issuance of new debt to retire existing obligations:
- Debt Repayment Plan: The Company intends to use a portion of the net proceeds to repurchase approximately $221.4 million aggregate principal amount of its outstanding 2.25% senior convertible notes due 2029.
- Repayment Cost: The repurchase of the 2029 notes will include accrued and unpaid interest, totaling approximately $350.9 million.
- Interest Rate Reduction: The new notes carry a significantly lower interest rate (0.50%) compared to the retired notes (2.25%).
- Extension of Maturity: The new debt extends the maturity horizon to 2032, compared to the 2029 maturity of the notes being retired.
Outlook, Management Commentary, and Risks
Use of Proceeds:
- Approximately $350.9 million allocated for the repurchase of 2029 notes (principal and interest).
- Remaining net proceeds designated for general corporate purposes, including commercialization expenses, clinical trials, R&D, capital expenditures, working capital, and G&A expenses.
- Conversion Rights: Holders may convert notes under specific conditions, including if the stock price exceeds 130% of the conversion price for 20 trading days in a quarter (after Q3 2026) or during the five business days following a 10-day period where the note trading price is below 98% of the conversion value.
- Redemption: The Company may not redeem the notes before May 21, 2029. After this date, redemption is permitted if the stock price exceeds 130% of the conversion price.
- Make-Whole Provisions: Fundamental changes or certain redemptions may trigger an increase in the conversion rate.
- The filing contains forward-looking statements regarding expected net proceeds and their use, which are subject to risks and uncertainties.
- Investors are cautioned that actual results may differ materially from projections due to factors beyond the Company's control.
- Full risk factors are referenced in the Company's most recent Form 10-K and 10-Q filings.
Investor Verification Checklist
- Net Proceeds Accuracy: Verify the final net proceeds of $508.5 million after deducting underwriting discounts and transaction expenses.
- Debt Repurchase Execution: Confirm the successful repurchase of the $221.4 million principal of 2029 notes and the total cash outflow of $350.9 million.
- Dilution Impact: Monitor the potential issuance of up to 11,729,182 shares upon conversion and the impact on earnings per share.
- Stock Price Thresholds: Track the Company's stock price relative to the $64.90 conversion price to assess the likelihood of conversion or redemption events.
- Liquidity Position: Review the Company's updated cash balance post-offering to assess runway for clinical trials and commercialization.